acterized by a progressive decrease with aging. Accordingly, we investigated the administration time-dependent antihypertensive efficacy of valsartan in elderly hypertensive patients. We studied 50 elderly patients with grade 1-2 essential hypertension (20 men), 67.0Ϯ0.8 years of age, randomly assigned to receive single daily valsartan monotherapy (160 mg/day) either on awakening or before bedtime. BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 hours before and after 3 months of therapeutic intervention. Physical activity was also monitored every minute by wrist actigraphy, and the information used to determine diurnal and nocturnal means of BP for each patient according to individual resting time. There was a highly significant BP reduction after 3 months of valsartan (PϽ0.001), similar for both treatment times (14.1 and 7.7 mm Hg reduction in the 24-hour mean of systolic and diastolic BP after valsartan on awakening; 14.7 and 8.2 mm Hg when valsartan was administered before bedtime). The day/night ratio measured as the nocturnal decline of BP relative to the diurnal mean was unchanged after valsartan on awakening (Ϫ2.1 and 0.6 for systolic and diastolic BP; PϾ0.184). This ratio was highly significantly increased (6.1 and 6.3 for systolic and diastolic BP, PϽ0.001) when valsartan was administered before bedtime. The reduction of nocturnal mean was, therefore, significantly larger after valsartan before bedtime (PϽ0.032). Results indicate that, at either the time of administration, 160 mg/day valsartan efficiently reduce BP for the whole 24 hours. In elderly hypertensive patients, characterized by a diminished nocturnal decline in BP, dosing time with valsartan might be chosen at bedtime, for improved efficacy during the nocturnal resting hours, and the potential reduction in cardiovascular risk associated to the normalized day/ night ratio.
P-209 EFFECTS OF VALSARTAN MONOTHERAPY ON THE CIRCADIAN BLOOD PRESSURE PROFILE OF PATIENTS WITH GRADE 1-2 ESSENTIAL HYPERTENSION
Angiotensin II receptor blockers (ARBs) are a relatively new class of antihypertensive medications that selectively and specifically antagonize the action of angiotensin II, a potent vasoconstrictor impacting blood pressure (BP) regulation. Valsartan is an orally active, specific, and selective ARB. After a single oral dose, the onset of its BP lowering action is within 2 hours, with peak effect occurring within 4 -6 hours. We investigated the effects of valsartan on the 24-hour BP profile of hypertensive patients. We studied 187 patients with grade 1-2 essential hypertension (63 men), 50.4Ϯ13.3 (meanϮSD) years of age, assigned to receive valsartan monotherapy (160 mg/day). BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours before and after 3 months of treatment. Physical activity was simultaneously monitored every minute by wrist actigraphy, and the information used to determine diurnal and nocturnal means of BP for each patient according to individual resting time. Valsartan treatment resulted in a highly statistically significant reduction in BP from baseline after 3 months of treatment (14.8 and 10.5 mm Hg reduction in the 24-hour mean of systolic and diastolic BP, respectively; PϽ0.001). The BP reduction was highly significant (after correcting for multiple testing) at each of the 24 hourly means (P always Ͻ0.001). There was no effect of valsartan on heart rate (increase in the 24-hour mean of 0.17 beats/min, Pϭ0.862). The circadian pattern of physical activity also remained unchanged (24-hour mean of 128 and 127 counts/min before and after treatment, respectively; Pϭ0.661). There was also a highly significant reduction (PϽ0.001) of 4.3 mm Hg in the 24-hour mean of pulse pressure (PP). Results indicate that, despite its relatively short half-life, 160 mg/day valsartan efficiently reduce BP for the whole 24 hours of the day. Moreover, valsartan significantly reduces PP during the 24 hours. Apart from the progressive rise of PP with aging, a significant increase in PP has been documented, among other groups of interest, in hypertensive patients with type 2 diabetes. Thus, valsartan could be chosen, for added cardiovascular risk reduction, in the treatment of the elderly and diabetics with elevated PP, an issue that deserves further prospective investigation. Amlodipine has been shown to be effective in reducing blood pressure (BP) throughout the day and night when given once daily. However, the potential chronopharmacologic differing effects on BP of amlodipine have only been addressed occasionally. We investigated the administration time-dependent antihypertensive efficacy of amlodipine given as added therapy in hypertensive patients. We studied 87 patients with uncontrolled grade 1-2 essential hypertension (45 men), 54.4Ϯ12.2 years of age, who were already taken an average of 1.8 drugs (mainly an ARB or ACE inhibitor combined with a diuretic). Patients were randomly assigned to receive a single daily dose of amlodipine (5 mg/day) either on awakening or before bedtime. BP was monitored at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours at baseline and after 3 months of therapeutic intervention. Physical activity was simultaneously monitored every min by wrist actigraphy, and the information used to determine diurnal and nocturnal means of BP for each patient according to individual resting time. After amlodipine on awakening, the reduction in BP was highly statistically significant (8.6 and 5.6 mm Hg reduction in the 24-hour mean of systolic and diastolic BP, respectively; PϽ0.001). The BP reduction was equivalent after amlodipine before bedtime (9.4 and 5.9 mm Hg reduction in systolic and diastolic BP, respectively; PϽ0.001). This BP reduction was similar during both daytime activity and nighttime resting hours, independently of dosing time, indicating a 24-hour therapeutic coverage of amlodipine administered either on awakening or before bedtime. The day/night BP ratio was slightly reduced after morning treatment (Ϫ0.6 and -1.2 for systolic and diastolic BP), but increased after evening treatment (1.4 and 1.3, respectively), although differences between treatment-times were not significant (Pϭ0.137). Results from this trial on uncontrolled hypertensive patients demonstrate that, independently of the time of administration with respect to the rest-activity cycle of each individual patient, a single daily dose of amlodipine efficiently reduces BP for the whole 24 hours of the day. The similar BP reduction observed for the diurnal and nocturnal means indicates that amlodipine does not modify the circadian pattern of BP variability.
